Biotech Values

[genisi]

GS-5885, as far as i can tell, is not active in genotypes 2 and 3

Indeed it is less potent against GT2/3 in replicon assays I've seen (don't recall clinical data), but data from phase II of sofosbuvir/daclatasvir regimen were quite good in GT2/3:

http://mobile.ilcapp.eu/EASL_161/poster_24858/program.aspx

So, I think it's quite possible that GILD's NS5A GS-5885 can produce similar results.

Edit: just kept reading and seen the following posts on the issue but I'll leave mine just because it has the link to the EASL poster...